Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

Yuyu Pharma

Status and phase: Completed; Phase 2

Conditions: Dry Eye

Treatments: Drug: 1% YP-P10 Ophthalmic Solution; Drug: 0.3% YP-P10 Ophthalmic Solution; Drug: YP-P10 Placebo Ophthalmic Solution (vehicle)

Study type: Interventional

Funder types: Industry

Identifiers

NCT05467293

YPP10-001

Details and patient eligibility

About

The objective of this study is to compare the safety and efficacy of YP-P10 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Full description

The clinical hypotheses for this study is that 0.3% YP-P10 Ophthalmic Solution twice daily (BID) and 1.0% YP-P10 Ophthalmic Solution BID are superior to YP-P10 Placebo Ophthalmic Solution (vehicle) for the primary endpoints of signs and symptoms of dry eye, as follows:

• Sign: Total corneal fluorescein staining score of the study eye using the modified NEI grading scale, measured by mean change from baseline (Visit 2, Pre- Controlled Adverse Environment [CAE®]) to Visit 6
• Symptom: Ocular discomfort score of both eyes using the Visual Analog Scale (VAS) Ocular Discomfort Scale, measured by mean change from baseline (Visit 2, Pre-CAE®) to Visit 6

Enrollment: 257 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Individuals eligible to participate in this study must meet all of the following criteria: 0. Be at least 18 years of age;

1. Provide written informed consent;

2. Be willing and able to comply with all study procedures;

3. Have a patient-reported history of dry eye for at least 6 months prior to Visit 1;

4. Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1;

5. Have a best corrected visual acuity (BCVA) of 0.7 logarithm of the minimum angle of resolution (logMAR) or better (Snellen equivalent score of 20/100 or better) in each eye at Visit 1;

6. Have a score of ≥ 2 for both eyes according to the Ora Calibra® Ocular Discomfort & 4- Symptom Questionnaire in at least one of the dry eye symptoms at Visits 1 and 2;

7. Have an unanesthetized Schirmer's Test score of ≤ 10 mm/5 minutes and ≥ 1 mm/5 minutes in at least one eye at Visits 1 and 2;

8. Have a corneal fluorescein staining score of ≥ 2 according to the Ora Calibra® Corneal and Conjunctival Staining Scale for Grading of Fluorescein Staining in at least one region in one eye at Visits 1 and 2 and a central score ≥ 1 in the same eye;

9. Have a conjunctival redness score ≥ 1 according to the Ora Calibra® Conjunctival Redness for Dry Eye Scale in at least one eye at Visits 1 and 2 pre-CAE®;

10. Demonstrate in the same eye(s) a response to the CAE® at Visits 1 and 2 as defined by:

    • Having at least a ≥1 point increase in fluorescein staining in the inferior region in at least one eye following CAE® exposure; a. Reporting an Ocular Discomfort score ≥ 3 at 2 or more consecutive time points in at least one eye during CAE® exposure (if a subject has an Ocular Discomfort rating of 3 at time = 0 for an eye, s/he must report an Ocular Discomfort rating of 4 for two consecutive measurements for that eye). Note: a subject cannot have an Ocular Discomfort score of 4 at time = 0);

11. Have at least one eye, the same eye, satisfy all criteria for 8, 9, 10 and 11 above;

12. A negative urine pregnancy test if female of childbearing potential (those who are not surgically sterilized [bilateral tubal ligation, hysterectomy or bilateral oophorectomy] or post-menopausal [12 months after last menses]) and must use adequate birth control through the study period. For non-sexually active females, abstinence may be regarded as an adequate method of birth control.)

Exclusion criteria

• Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study: 0. Have any clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction, lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;

1. Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;

2. Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;

3. Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;

4. Have used Restasis®, Xiidra®, or Cequa®, Eysuvis™ and Tyrvaya™ within 60 days of Visit 1;

5. Have had any ocular and/or lid surgeries in the past 6 months or have any planned ocular and/or lid surgeries over the study period;

6. Be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of Visit 1;

7. Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial (excluding medications allowed for the conduct of the study); the respective wash- out periods are required for the following medications:

   • Antihistamines (including ocular): 72 hours prior to Visit 1

     1. Oral aspirin or aspirin-containing products allowed if dose has been stable over past 30 days prior to Visit 1 and no change in dose is anticipated during the study period
     2. Corticosteroids or mast cell stabilizers (including ocular): 14 days prior to Visit 1
     3. Any medication (oral or topical) known to cause ocular drying that has not been administered as a stable dose for at least 30 days prior to Visit 1 and during the study
     4. All other topical ophthalmic preparations (including artificial tear substitutes) other than the study drops: 72 hours prior to Visit 1

8. Have an uncontrolled systemic disease;

9. Be a woman who is pregnant, nursing, or planning a pregnancy;

10. Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 6 (or early termination visit) if of childbearing potential. Non- childbearing potential is defined as a woman who is permanently sterilized (e.g., has had a hysterectomy or tubal ligation), or is post- menopausal (without menses for 12 consecutive months);

11. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; intrauterine device; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study;

12. Have a known allergy and/or sensitivity to the test article or its components;

13. Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;

14. Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1;

15. Be unable or unwilling to follow instructions, including participation in all study assessments and visits.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

257 participants in 3 patient groups, including a placebo group

0.3% YP-P10 Ophthalmic Solution

Active Comparator group

Treatment:

Drug: 0.3% YP-P10 Ophthalmic Solution

1% YP-P10 Ophthalmic Solution

Active Comparator group

Treatment:

Drug: 1% YP-P10 Ophthalmic Solution

YP-P10 Placebo Ophthalmic Solution (vehicle)

Placebo Comparator group

Treatment:

Drug: YP-P10 Placebo Ophthalmic Solution (vehicle)